NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets

Over $20 million in signed manufacturing contracts which include
premier biotech/pharma companies and research institutes

Elusys divestiture and R&D cuts expected to eliminate over $40 million in commitments and
reduce operating expenses by more than $13 million per year

Read more at globenewswire.com